Should patients hospitalized for COVID-19 routinely receive extra anticoagulation or go home with a course of antithrombotics? The first randomized controlled trial data are still emerging, leaving those questions to the realm of expert consensus statements with only observational and pre-COVID data from which to extrapolate. The key fulcrum on which the decision rests is how elevated venous thromboembolism (VTE) risk is versus how much bleeding occurs in COVID-19 patients, noted speakers at a Pulmonary Embolism Response Team Consortium webinar on Wednesday. A widely cited meta-analysis in C...